Sculptor Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Sculptor Capital’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,663	Closed	-$681K	–	287
2019 Q3	$681K	Sell	4,663 -337	-7%	-$58.7K	0.01%	242
2019 Q2	$1.04M	Hold	5,000	–	–	0.01%	209
2019 Q1	$1.04M	Buy	+5,000	New	+$1.1M	0.01%	163
2018 Q4	–	Sell	-10,027	Closed	-$2.27M	–	245
2018 Q3	$2.27M	Buy	+10,027	New	+$1.62M	0.01%	141

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sculptor Capital's CRBP Position: Q4 2019 in Review

Sculptor Capital sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 4,663 shares — an estimated $681K sold.

Sculptor Capital first reported a position in CRBP in Q3 2018 and held it in 4 quarters. The position peaked at $2.27M in Q3 2018. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

Sculptor Capital reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Sculptor Capital sold 4,663 Corbus Pharmaceuticals shares in Q4 2019, an estimated $681K.
Sculptor Capital first reported a position in Corbus Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Sculptor Capital's Corbus Pharmaceuticals position peaked at $2.27M in Q3 2018.
105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Sculptor Capital's 13F filing for Q4 2019, filed 14 Feb 2020.